Saturday, July 11, 2026

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 22 of 116
  1. Selpercatinib

    Eli Lilly and Company

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  2. Sevabertinib

    Bayer HealthCare AG

    Advanced Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  3. Sigvotatug Vedotin

    Pfizer

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  4. Somatostatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gallbladder Neoplasms

    phase 3 small molecule completed

    1 trial
  5. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    4 trials
  6. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial
  7. Soquelitinib

    Corvus Pharmaceuticals

    Peripheral T-Cell Lymphoma, Not Otherwise Specified

    phase 3 small molecule active

    1 trial
  8. Sorafenib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials
  9. Sorafenib

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial
  10. Sorafenib (Nexavar, BAY43-9006)

    Bayer HealthCare AG

    Carcinoma

    phase 3 small molecule completed

    1 trial
  11. Sorafenib (Nexavar, BAY43-9006)

    Bayer HealthCare AG

    Carcinoma, Hepatocellular

    phase 3 small molecule completed

    1 trial
  12. Standard First-Line Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable Colorectal Cancer

    phase 3 small molecule active

    1 trial
  13. Standard of Care

    AbbVie

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  14. Standard of Care

    Telix Innovations

    Metastatic Prostate Cancer

    phase 3 small molecule terminated

    1 trial
  15. Standard treatment: Control arm

    United Therapeutics Europe Ltd

    Cervical Carcinoma

    phase 3 other active

    1 trial
  16. Subcutaneous Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial
  17. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mediastinal Neoplasms

    phase 3 other active

    1 trial
  18. Subxiphoid uniportal VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Neoplasms

    phase 3 other completed

    1 trial
  19. Suprefact Depot 9 for low-volume metastatic castration-sensitive prostate cancer

    Disc Medicine

    low-volume metastatic castration-sensitive prostate cancer

    phase 3 small molecule active

    1 trial
  20. Surgery and HIPEC with Lobaplatin

    Universal Integrated

    Colorectal Neoplasms

    phase 3 other active

    1 trial
  21. Surovatamig

    AstraZeneca

    Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

    phase 3 small molecule active

    1 trial
  22. Systematic oral health education

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor of Head and/or Neck

    phase 3 other completed

    1 trial
  23. TAK-788

    Takeda

    Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial
  24. TAMOXIFEN for Breast cancer

    Shanghai Reinovax Biologics Co.,LTD

    Breast cancer

    phase 3 small molecule active

    1 trial
  25. TAP-144-SR(6M)

    Takeda

    Premenopausal Breast Cancer

    phase 3 small molecule completed

    1 trial
  26. TAP-144-SR(6M)

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial
  27. TARA-002

    Protara Therapeutics

    Bladder (Urothelial, Transitional Cell) Cancer

    phase 3 small molecule active

    1 trial
  28. TAS6417-301

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial
  29. TAXOL for Recurrent or Metastatic HER2 Ne…

    Lacuna Pharma Pty Ltd

    Recurrent or Metastatic HER2 Negative Breast Cancer

    phase 3 small molecule active

    1 trial
  30. TCM

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  31. THIO-104

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  32. TPST-1120

    Tempest Therapeutics

    Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial
  33. TRIO041

    Wuhan Createrna Science and Technology Co., Ltd

    Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

    phase 3 small molecule active

    1 trial
  34. Tamoxifen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Female

    phase 3 small molecule active

    1 trial
  35. Tamoxifen

    Pfizer

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial
  36. Tamoxifen

    International Peace Maternity and Child Health Hospital

    Breast Cancer

    phase 3 small molecule completed

    1 trial
  37. Tamoxifen Viatris 20 mg tabletter.

    The George Institute

    Breast Cancer

    phase 3 small molecule active

    1 trial
  38. Tarlatamab

    Amgen

    Extensive-Stage Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial
  39. Tarlatamab

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial
  40. Taselisib

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule terminated

    1 trial
  41. Tasisulam-sodium

    Eli Lilly and Company

    Melanoma

    phase 3 small molecule terminated

    1 trial
  42. Taxane

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial
  43. Taxotere , Epirubicin

    Hospital Authority, Hong Kong

    Breast Cancer

    phase 3 small molecule completed

    1 trial
  44. Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial
  45. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial
  46. Tecentriq 840 mg concentrate for solution for infusion

    Novo Nordisk A/S

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 3 small molecule active

    1 trial
  47. Tegafur-Gimeracil-Oteracil Potassium

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasm

    phase 3 small molecule completed

    1 trial
  48. Telisotuzumab Adizutecan

    AbbVie

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.